Human Genetic Variation Alters Anthrax Toxin Sensitivity
Martchenko, Candille et al., PNAS
Researchers at Stanford University School of Medicine show that genetic variation affecting capillary morphogenesis gene 2, or CMG2, dramatically alters toxin sensitivity in humans. In its analysis, the team reports on "a CMG2 single-nucleotide polymorphism occurring frequently in African and European populations [that they found] independently altered toxin uptake." The group goes on to suggest "testing of genomically characterized human cell populations may offer a broadly useful strategy for elucidating effects of genetic variation on infectious disease susceptibility."
FDA ‘Interested in Collaborating’ With Personal Genomics Firms to Track AEs
November 19, 2008
In marketing ancestry and disease-predisposition genetic testing services directly to consumers, personal genomics companies are building large electronic databases of clinical and genomic information. The FDA believes these databases can help the agency track adverse reactions in a post-marketing setting.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Breast Cancer Test Makers Will Attempt to Sway UK's NICE in Wake of Initial Negative Opinion
February 8, 2012 / Pharmacogenomics Reporter - Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 8, 2012 / Pharmacogenomics Reporter - Spring Release Planned for XDx AlloMap Utility Data in Riskiest Months Following Heart Transplant
February 8, 2012 / Pharmacogenomics Reporter - Myriad Presents Fourth Study Showing Prolaris Score Predicts Prostate Cancer Aggressiveness
February 8, 2012 / Pharmacogenomics Reporter - MDx/CDx Focus: Siemens Inks Companion Dx Partnerships; FDA Accepts Roche's Pertuzumab BLA
February 8, 2012 / Pharmacogenomics Reporter